Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome-wide gene expression analysis of the cancer cell lines after treatiment with telomerase inhibitor Imetelstat (GRN163L)

ABSTRACT: Transcriptome-wide gene expression analysis of the cancer cell lines after treatiment with telomerase inhibitor Imetelstat (GRN163L)

PROVIDER: PRJNA417570 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Transcriptome-wide gene expression analysis of the cancer cell lines after treatiment with telomerase inhibitor Imetelstat (GRN163L)

Project description:GRN163L is a potent and specific telomerase inhibitor and in clinical trials for cancer treatment. To identify the biomarker that might predict response to telomease based therapy, gene expression analysis of the cancer cell lines after treatiment with telomerase inhibitor Imetelstat (GRN163L) was performed.

2018-07-19 | GSE106539 | GEO

Telomerase inhibitor TMPyP4 induced widespread gene expression

2008-08-25 | GSE9710 | GEO

Telomerase inhibitor TMPyP4 induced gene expression

Project description:The effect of TMPyP4, the well established anticancer telomerase inhibitor on genome wide expression of genes was investigated Keywords: Time course

2007-06-20 | GSE5226 | GEO

Telomerase inhibitor TMPyP4 induced widespread gene expression

Project description:The effect of TMPyP4, the well established anticancer telomerase inhibitor on genome wide expression of genes, analyzed across different cell-lines, was investigated Keywords: Comparative gene-expression profiling Cells were treated with TMPyP4 for 48 hours before RNA isolation. Untreated cells were taken as controls and the TMPyP4 treated cells as treatments. Experiments in each cell-line (A549 and HeLa S3) were replicated four times.

2010-06-20 | E-GEOD-9710 | biostudies-arrayexpress

Telomerase inhibitor TMPyP4 induced gene expression

Project description:The effect of TMPyP4, the well established anticancer telomerase inhibitor on genome wide expression of genes was investigated Keywords: Time course Cells were treated with TMPyP4 for either 24 or 48 hours before RNA isolation.Untreated cells were taken as controls and the TMPyP4 treated cells as treatments. Experiments at each time point were replicated four times.

2010-06-10 | E-GEOD-5226 | biostudies-arrayexpress

MAT2A inhibitor in cancer cell lines

Project description:MAT2A inhibitor in cancer cell lines

| PRJNA679231 | ENA

A genome-wide screen for essentiality upon telomerase inhibition identifies a novel p53 regulator, C16ORF72/TAPR1

Project description:Telomere erosion contributes to age-associated tissue dysfunction and senescence, and p53 plays a crucial role in this response. We undertook a genome-wide screen to identify gene deletions that sensitized p53-positive human cells to loss of telomere integrity, and uncovered a previously unannotated gene, C16ORF72, which we term Telomere Attrition and p53 Response 1: TAPR1. CRISPR-Cas9 mediated deletion of TAPR1 led to elevated p53 and induction of p53 transcriptional targets. TAPR1-disrupted cells exhibited a synthetic-sick relationship with the loss of telomerase, or treatment with the topoisomerase II inhibitor doxorubicin. Stabilization of p53 with nutlin-3a further decreased cell fitness in cells lacking TAPR1 or telomerase, whereas deletion of TP53 rescued the decreased fitness of TAPR1-deleted cells. We propose that TAPR1 regulates p53 turnover, thereby tapering the p53-dependent response to telomere erosion. We discuss the possible implications of such a mechanism in the preservation of genome integrity during senescence or aging.

2021-03-04 | PXD022128 | Pride

MST-312: a telomerase inhibitor effectively blocking MYC oncogenic functions

Project description:MST-312: a telomerase inhibitor effectively blocking MYC oncogenic functions

| PRJNA309377 | ENA

Genome-wide TNFα-induced p65 binding before and after telomerase inhibition in HeLa cells

Project description:Chromatin immunoprecipitation sequencing (ChIP-seq) was performed to analyze the effect of telomerase inhibition on TNFα-induced genome-wide p65 binding in HeLa cells. By obtaining over 40 million uniquely mappable reads per sample from ChIP-seq, maps for TNFα-induced p65 binding in absence and presence of an hTERT inhibitor, MST-312, were generated. As expected, TNFα treatment significantly increased genome-wide p65 occupancy. Interestingly, when cells were treated with MST-312 prior to TNFα stimulation, the number of p65 binding sites was reduced. In addition, some binding sites, including important p65 targets like IL6 and TNF, showed a reduced p65 occupancy with a minimum fold change of 1.5, after MST-312 exposure. Taken together, our ChIP-seq data indicate that telomerase is required for optimal p65 binding at a small proportion of p65 target sites upon inflammatory stimuli.

2012-11-26 | GSE41100 | GEO

Genome-wide TNFM-NM-1-induced p65 binding before and after telomerase inhibition in HeLa cells

Project description:Chromatin immunoprecipitation sequencing (ChIP-seq) was performed to analyze the effect of telomerase inhibition on TNFM-NM-1-induced genome-wide p65 binding in HeLa cells. By obtaining over 40 million uniquely mappable reads per sample from ChIP-seq, maps for TNFM-NM-1-induced p65 binding in absence and presence of an hTERT inhibitor, MST-312, were generated. As expected, TNFM-NM-1 treatment significantly increased genome-wide p65 occupancy. Interestingly, when cells were treated with MST-312 prior to TNFM-NM-1 stimulation, the number of p65 binding sites was reduced. In addition, some binding sites, including important p65 targets like IL6 and TNF, showed a reduced p65 occupancy with a minimum fold change of 1.5, after MST-312 exposure. Taken together, our ChIP-seq data indicate that telomerase is required for optimal p65 binding at a small proportion of p65 target sites upon inflammatory stimuli. Examination of p65 binding in HeLa cells in absence and presence of TNFM-NM-1 and MST-312.

2012-11-26 | E-GEOD-41100 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data